LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
December 14, 2022 03:19 ET
|
LumiraDx Inc
LONDON, Dec. 14, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has received $14.2M in grants from the Bill &...
Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community Settings
December 08, 2022 03:01 ET
|
LumiraDx Inc
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced findings from its first annual U.K. survey, “Point of...
Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
December 08, 2022 03:01 ET
|
LumiraDx Inc
WALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced findings from its second annual “Point of Care...
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
November 14, 2022 02:58 ET
|
LumiraDx Inc
Early customers include GP offices and other community-based healthcare settingsLatest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and...
Mit HbA1c-Test erweitert LumiraDx erneut sein Mikrofluidik-Point-of-Care-Diagnostik-Portfolio
November 14, 2022 02:58 ET
|
LumiraDx Inc
Zu den ersten Kunden gehören Allgemeinarztpraxen und andere patientennahe GesundheitseinrichtungenJüngste Zahlen, die im Rahmen des Weltdiabetestages veröffentlicht wurden, zeigen, dass inzwischen 1...
LumiraDx Reports Third Quarter 2022 Results
November 09, 2022 07:00 ET
|
LumiraDx Inc
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the third...
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
November 02, 2022 07:23 ET
|
LumiraDx Inc
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results...
LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry
October 12, 2022 04:00 ET
|
LumiraDx Inc
LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Today, LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced it has been named by Frost & Sullivan as the 2022 Europe...
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
September 22, 2022 04:12 ET
|
LumiraDx Inc
LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Today, LumiraDx Limited (Nasdaq: LMDX) a next-generation point of care diagnostics company, in partnership the British In Vitro Diagnostics Association,...
LumiraDx Reports Second Quarter 2022 Results
August 18, 2022 07:00 ET
|
LumiraDx Inc
LONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the second...